Cargando…
Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts
The utility of plasma amyloid beta (Aβ) and tau levels for the clinical diagnosis of Alzheimer’s disease (AD) dementia has been controversial. The main objective of this study was to compare Aβ42 and tau levels measured by the ultra-sensitive immunomagnetic reduction (IMR) assays in plasma samples c...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522888/ https://www.ncbi.nlm.nih.gov/pubmed/28790911 http://dx.doi.org/10.3389/fnagi.2017.00226 |
_version_ | 1783252239494676480 |
---|---|
author | Lue, Lih-Fen Sabbagh, Marwan N. Chiu, Ming-Jang Jing, Naomi Snyder, Noelle L. Schmitz, Christopher Guerra, Andre Belden, Christine M. Chen, Ta-Fu Yang, Che-Chuan Yang, Shieh-Yueh Walker, Douglas G. Chen, Kewei Reiman, Eric M. |
author_facet | Lue, Lih-Fen Sabbagh, Marwan N. Chiu, Ming-Jang Jing, Naomi Snyder, Noelle L. Schmitz, Christopher Guerra, Andre Belden, Christine M. Chen, Ta-Fu Yang, Che-Chuan Yang, Shieh-Yueh Walker, Douglas G. Chen, Kewei Reiman, Eric M. |
author_sort | Lue, Lih-Fen |
collection | PubMed |
description | The utility of plasma amyloid beta (Aβ) and tau levels for the clinical diagnosis of Alzheimer’s disease (AD) dementia has been controversial. The main objective of this study was to compare Aβ42 and tau levels measured by the ultra-sensitive immunomagnetic reduction (IMR) assays in plasma samples collected at the Banner Sun Health Institute (BSHRI) (United States) with those from the National Taiwan University Hospital (NTUH) (Taiwan). Significant increase in tau levels were detected in AD subjects from both cohorts, while Aβ42 levels were increased only in the NTUH cohort. A regression model incorporating age showed that tau levels identified probable ADs with 81 and 96% accuracy in the BSHRI and NTUH cohorts, respectively, while computed products of Aβ42 and tau increased the accuracy to 84% in the BSHRI cohorts. Using 382.68 (pg/ml)(2) as the cut-off value, the product achieved 92% accuracy in identifying AD in the combined cohorts. Overall findings support that plasma Aβ42 and tau assayed by IMR technology can be used to assist in the clinical diagnosis of AD. |
format | Online Article Text |
id | pubmed-5522888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55228882017-08-08 Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts Lue, Lih-Fen Sabbagh, Marwan N. Chiu, Ming-Jang Jing, Naomi Snyder, Noelle L. Schmitz, Christopher Guerra, Andre Belden, Christine M. Chen, Ta-Fu Yang, Che-Chuan Yang, Shieh-Yueh Walker, Douglas G. Chen, Kewei Reiman, Eric M. Front Aging Neurosci Neuroscience The utility of plasma amyloid beta (Aβ) and tau levels for the clinical diagnosis of Alzheimer’s disease (AD) dementia has been controversial. The main objective of this study was to compare Aβ42 and tau levels measured by the ultra-sensitive immunomagnetic reduction (IMR) assays in plasma samples collected at the Banner Sun Health Institute (BSHRI) (United States) with those from the National Taiwan University Hospital (NTUH) (Taiwan). Significant increase in tau levels were detected in AD subjects from both cohorts, while Aβ42 levels were increased only in the NTUH cohort. A regression model incorporating age showed that tau levels identified probable ADs with 81 and 96% accuracy in the BSHRI and NTUH cohorts, respectively, while computed products of Aβ42 and tau increased the accuracy to 84% in the BSHRI cohorts. Using 382.68 (pg/ml)(2) as the cut-off value, the product achieved 92% accuracy in identifying AD in the combined cohorts. Overall findings support that plasma Aβ42 and tau assayed by IMR technology can be used to assist in the clinical diagnosis of AD. Frontiers Media S.A. 2017-07-24 /pmc/articles/PMC5522888/ /pubmed/28790911 http://dx.doi.org/10.3389/fnagi.2017.00226 Text en Copyright © 2017 Lue, Sabbagh, Chiu, Jing, Snyder, Schmitz, Guerra, Belden, Chen, Yang, Yang, Walker, Chen and Reiman. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Lue, Lih-Fen Sabbagh, Marwan N. Chiu, Ming-Jang Jing, Naomi Snyder, Noelle L. Schmitz, Christopher Guerra, Andre Belden, Christine M. Chen, Ta-Fu Yang, Che-Chuan Yang, Shieh-Yueh Walker, Douglas G. Chen, Kewei Reiman, Eric M. Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts |
title | Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts |
title_full | Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts |
title_fullStr | Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts |
title_full_unstemmed | Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts |
title_short | Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts |
title_sort | plasma levels of aβ42 and tau identified probable alzheimer’s dementia: findings in two cohorts |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522888/ https://www.ncbi.nlm.nih.gov/pubmed/28790911 http://dx.doi.org/10.3389/fnagi.2017.00226 |
work_keys_str_mv | AT luelihfen plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT sabbaghmarwann plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT chiumingjang plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT jingnaomi plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT snydernoellel plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT schmitzchristopher plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT guerraandre plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT beldenchristinem plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT chentafu plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT yangchechuan plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT yangshiehyueh plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT walkerdouglasg plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT chenkewei plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts AT reimanericm plasmalevelsofab42andtauidentifiedprobablealzheimersdementiafindingsintwocohorts |